Zenapax / Daclizumab

Modified on 2009/10/14 21:45 by admin
Zenapax, also known as daclizumab, belongs to a group of medications known as immunosuppressive agents and is used to lower the body's natural immunity in patients who receive kidney transplants. Zenapax prevents the body's white blood cells from rejecting the transplanted kidney. This effect, however, may prevent the body from properly fighting infections. The U.S. Food and Drug Administration (FDA) approved Zenapax in 1997. The medication is made by Roche.

Potential side effects of Zenapax include, but may not be limited to, chest pain, coughing, dizziness, fever, nausea, rapid heart rate, shortness of breath, swelling of the feet or lower legs, trembling or shaking of the hands or feet and vomiting.

In August 2003, the FDA and Roche revised the WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and CLINICAL STUDIES sections of the prescribing information to include important new safety information describing the increased mortality seen in a cardiac transplant study and other updated information regarding hypersensitivity reactions. Other sections of the Zenapax labeling impacted by the addition of the information from the cardiac transplant study have also been revised.

See your doctor if you have experienced an adverse reaction after using Zenapax. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Transplantation & Immunosuppressant Drugs: Overview
  2. Balance Problems: Overview
  3. Lung & Airway Disorders
  4. Nausea: Overview
  Name Size